Forte Biosciences reports positive results from Phase Ib trial for vitiligo
Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.
Clinical Trials
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
MAIA reports positive efficacy results from Phase II trial for NSCLC
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
Bayer enters clinical trials alliance with CU Anschutz and partners
Prilenia and Ferrer begin Phase III trial of Huntington’s therapy
First patient treated in fifth cohort of Anixa’s ovarian cancer trial
Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment
